nilutamide and Cancer of Prostate studies

Research Excerpts

Excerpt	Relevance	Reference
"A total of 26 previously untreated patients with metastatic carcinoma of the prostate received the pure nonsteroidal antiandrogen nilutamide as a single agent."	7.68	Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. ( Boccardo, F; Costantini, M; Decensi, AU; Giuliani, L; Guarneri, D; Martorana, G; Paoletti, MC; Positano, N, 1991)
"MEDLINE (1980-1995) and CANCERLIT (1991-1995) were searched for English-language publications using the terms nilutamide, bicalutamide, and flutamide alone, and either nilutamide or androgen antagonists in combination with prostatic neoplasms."	4.79	Nilutamide: an antiandrogen for the treatment of prostate cancer. ( Dole, EJ; Holdsworth, MT, 1997)
"Nilutamide was generally well tolerated, though visual disorders, gastrointestinal disorders, and alcohol intolerance were reported in patients receiving nilutamide."	3.77	Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. ( Du Plessis, DJ, 1991)
"Only Flutamide has been studied in monotherapy of prostatic cancer patients."	3.76	Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. ( Schröder, FH, 1990)
"A total of 26 previously untreated patients with metastatic carcinoma of the prostate received the pure nonsteroidal antiandrogen nilutamide as a single agent."	3.68	Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. ( Boccardo, F; Costantini, M; Decensi, AU; Giuliani, L; Guarneri, D; Martorana, G; Paoletti, MC; Positano, N, 1991)
"We report the case of a 69-year-old patient treated for stage C adenocarcinoma of the prostate with the combination of the luteinizing hormone-releasing hormone agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide and the antiandrogen nilutamide (Anandron) who developed simultaneous liver and lung toxicity."	3.68	Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. ( Cusan, L; Dupont, A; Gomez, JL; Labrie, F; Tremblay, M, 1992)
"Men with histologically confirmed prostate cancer not amenable to curative surgery or radiation therapy were eligible for the study if they had radiographic or PSA progression on at least one antiandrogen (not nilutamide) despite continued androgen suppression and standard antiandrogen withdrawal periods."	2.71	A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. ( Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ, 2005)
"Osteoporosis was documented in at least one site evaluated in 41 patients (37%)."	2.71	Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. ( Crook, J; Dahrouge, S; Malone, S; Perry, G; Segal, R, 2005)
" Nilutamide was well tolerated in the long term with no increase in the incidence of drug specific adverse events."	2.68	Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. ( De Reijke, TM; Debruyne, FM; Dijkman, GA; Janknegt, RA, 1997)
"Patients with advanced prostate cancer have a beneficial effect from maximal androgen blockade in terms of the subjective and objective delay of progression and median duration of survival, although side effects do occur more often in the combination treatment than in testicular suppression alone."	2.68	Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group. ( Debruyne, FM; Dijkman, GA; Fernandez del Moral, P; Janknegt, RA, 1995)
"toxicity (65%), hemeralopia (27%), and alcohol intolerance (6."	2.67	Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. ( Boccardo, F; Decensi, AU; Fioretto, L; Giuliani, L; Guarneri, D; Macaluso, MP; Martorana, G; Mini, E; Periti, P; Santi, L, 1991)
"Patients with metastatic prostatic cancer without prior endocrine manipulation underwent orchiectomy and were randomized to 1 of 2 groups receiving nilutamide (225 patients) or placebo (232)."	2.67	Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. ( Abbou, CC; Bartoletti, R; Bernstein-Hahn, L; Bracken, B; Brisset, JM; Chisholm, G; Crawford, ED; Da Silva, FC; Debruyne, FM; Janknegt, RA, 1993)
"Thirty-six men with disseminated prostatic cancer and elevated plasma levels of prostatic acid phosphatase were randomly assigned to two groups."	2.66	Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). ( Billebaud, T; Costa, P; Dahan, R; Fiet, J; Grise, P; Husson, JM; Kuhn, JM; Louis, JF; Moulonguet, A; Navratil, H, 1989)
" Nausea and vomiting were the most common adverse events reported in Nilutamide group."	2.61	Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis. ( Chhabra, M; Rashid, M; Shamshavali, K, 2019)
"The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part."	2.49	[Hormonal treatment in prostate cancer]. ( Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F, 2013)
"Unfortunately, every treatment for prostate cancer has adverse effects with negative impact in health-related quality of life."	2.42	Monotherapy in advanced prostate cancer: an overview. ( Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N, 2004)
"Bicalutamide has a more favourable side-effect profile than the other antiandrogens and is more likely to promote compliance."	2.42	The role of antiandrogen monotherapy in the treatment of prostate cancer. ( Anderson, J, 2003)
"In locally advanced M0 prostate cancer bicalutamide 150 mg monotherapy seems equivalent to castration in terms of overall survival and time to progression."	2.42	Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. ( Cardi, A; Di Silverio, F; Sciarra, A, 2004)
"Many patients with prostate cancer for whom hormonal therapy is indicated are still physically and sexually active; quality of life is therefore a vital issue when considering treatment options."	2.41	Antiandrogen monotherapy: indications and results. ( Iversen, P, 2002)
"In advanced prostate cancer, androgen suppression (AS) by surgery or drugs controls testicular hormone secretion, and the further addition of an antiandrogen such as nilutamide, flutamide, or cyproterone acetate is referred to as maximum androgen blockade (MAB)."	2.41	Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. ( , 2000)
"Appropriate patients with metastatic prostate cancer should be informed of the potential benefits, toxicities, and out-of-pocket expenditures."	2.41	Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. ( Bennett, CL; Crawford, ED; DeMasi, V; Sartor, O; Schellhammer, PF; Schmitt, B; Wilt, TJ, 2001)
" Bicalutamide is available in a convenient one tablet, once-a-day dosing regimen, is at least as effective as flutamide and is better tolerated in terms of diarrhea."	2.40	Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen. ( Sarosdy, MF, 1999)
"This article provides a summary of the pharmacodynamic properties of major antiandrogens as well as an extensive review of their tolerability."	2.40	Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. ( De Angelis, M; De Benedetto, G; Migliari, R; Murru, M; Muscas, G; Verdacchi, T, 1999)
" Assuming that each modality is equally effective, emphasis should be placed on increasing patient tolerance and compliance by the use of long-acting, nontoxic treatments with simple dosing regimens and minimal side effects."	2.40	Androgen deprivation for prostatic carcinoma: a rationale for choosing components. ( Chatelain, C; Fourcade, RO, 1998)
"Prostatic cancer is the second most common cause of cancer death in males."	2.40	Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. ( Denis, L; Mahler, C; Verhelst, J, 1998)
"Nilutamide has been less extensively investigated, but the clinical utility of this agent, except for use in combined therapy, would appear to be somewhat limited by a high incidence of drug-related side effects."	2.40	Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? ( Boccon-Gibod, L, 1998)
"Prostate cancer is the most frequent cancer diagnosed in American men today."	2.38	Antiandrogenic drugs. ( McLeod, DG, 1993)
" In the rat, bioavailability by the oral route was complete."	2.38	Pharmacokinetics and metabolism of nilutamide. ( Creaven, PJ; Pendyala, L; Tremblay, D, 1991)
"Nilutamide is a nonsteroidal antiandrogen which is used in the treatment of prostate cancer."	1.51	Synthesis of Deuterium Labeled 5, 5-Dimethyl-3-(α, α, α-trifluoro-4-nitro-m-tolyl) Hydantoin. ( Bolla, RS; Gandikota, NM; Kasi Viswanath, IV, 2019)
"We also found an increased risk of arrhythmia and conduction disorder in men with preexisting CVD."	1.46	Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. ( Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X, 2017)
"Nilutamide appears to be an effective secondary hormonal therapy in patients with AIPC and is associated with a mild toxicity profile."	1.33	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. ( Kantoff, PW; Lifsey, D; Nakabayashi, M; Oh, WK; Regan, MM; Sartor, O; Taplin, ME, 2005)
"We used rat prostate cancer cell stable transfectants that lacked either endogenous fibroblast growth factor (FGF)-1 secondary to constitutive expression of FGF-1 antisense RNA (aFa2-transfectants) or endogenous FGF-2 isoforms secondary to constitutive expression of FGF-2 antisense RNA (bFa9-transfectants) to examine the potential synergistic effects of mitogen and androgen as modulators of proliferation."	1.31	Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer. ( Shain, SA, 2001)
"Nilutamide is a little used antiandrogen that has a chemical structure distinct from that of the other two antiandrogens, flutamide and bicalutamide."	1.31	Nilutamide: possible utility as a second-line hormonal agent. ( Desai, A; Stadler, WM; Vogelzang, NJ, 2001)
" Dose-response curves were analyzed for 5alpha-dihydrotestosterone, the most active androgen in normal prostate, and androstenedione, a major androgen derived from the adrenals."	1.30	Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. ( Balk, SP; Bubley, GJ; Fenton, MA; Fertig, AM; Kolvenbag, G; Shuster, TD; Taplin, ME, 1997)
"Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported."	1.30	Antiandrogen withdrawal syndrome with nilutamide. ( Gerridzen, RG; Huan, SD; Stewart, DJ; Yau, JC, 1997)
" In the subjects treated with the LHRH agonist, 6 months after discontinuation of long-term administration the mean (+/- SEM) LH had risen to 36."	1.29	Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. ( Boccardo, F; Decensi, A; Fontana, V; Guarneri, D; Marroni, P; Minuto, F; Padovani, P; Torrisi, R, 1993)
"Transfection studies in the human prostate cancer cell line LNCaP examine the ability of dihydrotestosterone (DHT), hydroxyflutamide (HO-FLU), cyproterone acetate (Cypro."	1.29	Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. ( Govindan, MV; Koutsilieris, M; Pagé, N; Warriar, N, 1994)
"Nilutamide is a new, specific synthetic antiandrogen, released in several countries for the treatment of metastatic carcinoma of the prostate."	1.28	Nilutamide pneumonitis: a report on eight patients. ( Braud, ML; Camus, P; Coudert, B; Foucher, P; Gabez, P; Lacroix, S; Mabille, JP; Pfitzenmeyer, P; Piard, F, 1992)
"Nilutamide therapy was then resumed for five weeks and induced the recurrence of clinical, functional and alveolar abnormalities."	1.28	Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis. ( Akoun, GM; Gauthier-Rahman, S; Kuntz, D; Liote, F; Liote, HA, 1990)
" Multicenter trials will be necessary to delineate the place of LHRH agonist alone or LHRH agonist combined with an antiandrogen in the treatment of prostatic cancer."	1.27	Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. ( Faure, N; Fazekas, AT; Jean, C; Laroche, B; Lemay, A; Plante, R; Robert, G; Roy, R; Thabet, M, 1983)
"in 1941, hormonal treatment of advanced prostatic cancer has been directed primarily at neutralizing testicular androgens by orchiectomy or estrogen therapy."	1.27	[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]. ( Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE, 1986)
"Proliferation of all AXC/SSh prostate cancer cell lines during propagation on media containing fetal bovine serum was not altered by changes in media testosterone concentration through the range 10(-6) to 10(-9) M."	1.27	Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen. ( Huot, RI; Shain, SA, 1986)
"To improve the inhibition of prostate cancer growth obtained by surgical or chemical castration (estrogens or LHRH analogs), blockade of the action of residual androgens of adrenal origin has been proposed."	1.27	Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. ( Fiet, J; Moguilewsky, M; Raynaud, JP; Tournemine, C, 1986)
" The plasma decay of Anandron after the absorption phase was biexponential in all patients, with the terminal phase half-life ranging from 23."	1.27	Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate. ( Bertagna, C; Creaven, PJ; Huben, R; Pendyala, L; Tremblay, D, 1988)
" Since uninterrupted administration of the antiandrogen is of the outmost importance for the successful therapy of prostatic cancer, the availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment."	1.27	Ocular toxicity of Anandron in patients treated for prostatic cancer. ( Dupont, A; Harnois, C; Labrie, F; Malenfant, M, 1986)

Research

Studies (146)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Median Testosterone After 84 Days of Enzalutamide

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)

Timeframe	Studies, this research(%)	All Research%
pre-1990	36 (24.66)	18.7374
1990's	68 (46.58)	18.2507
2000's	35 (23.97)	29.6817
2010's	7 (4.79)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Cogan, PS	1
Koch, TH	1
Payen, O	1
Top, S	1
Vessières, A	1
Brulé, E	1
Plamont, MA	1
McGlinchey, MJ	1
Müller-Bunz, H	1
Jaouen, G	1
Haque, R	1
UlcickasYood, M	1
Xu, X	1
Cassidy-Bushrow, AE	1
Tsai, HT	1
Keating, NL	1
Van Den Eeden, SK	1
Potosky, AL	1
Rashid, M	1
Shamshavali, K	1
Chhabra, M	1
Deka, R	1
Rose, BS	1
Bryant, AK	1
Sarkar, RR	1
Nalawade, V	1
McKay, R	1
Murphy, JD	1
Simpson, DR	1
Bolla, RS	1
Gandikota, NM	1
Kasi Viswanath, IV	1
Kokulnathan, T	1
Karthik, R	1
Chen, SM	1
Kumar, JV	1
Sakthinathan, S	1
Bastide, C	1
Bruyère, F	1
Karsenty, G	1
Guy, L	1
Rozet, F	1
Lourenço, EP	1
Nzwalo, H	1
Sampaio, MR	1
Brito, H	1
Chan, P	1
Odel, JG	1
Madan, RA	1
Gulley, JL	2
Schlom, J	2
Steinberg, SM	2
Liewehr, DJ	1
Dahut, WL	1
Arlen, PM	2
Brower, V	1
Choo, R	3
Danjoux, C	3
Gardner, S	2
Morton, G	3
Szumacher, E	4
Loblaw, DA	2
Cheung, P	3
Pearse, M	2
de Reijke, T	1
Derobert, E	1
Iversen, P	3
Bennett, CL	2
Raisch, DW	1
Sartor, O	4
Anderson, J	1
Kassouf, W	1
Tanguay, S	1
Aprikian, AG	1
Edouard, A	1
Robinel, R	1
Rat, C	1
Lombard, F	1
Lorinet, C	1
Escarmant, P	1
Sciarra, A	1
Cardi, A	1
Di Silverio, F	1
Baltogiannis, D	1
Giannakopoulos, X	1
Charalabopoulos, K	1
Sofikitis, N	1
Chander, S	1
Pearce, A	1
Deboer, G	1
Loblaw, A	1
Woo, T	1
Peyromaure, M	1
Delongchamps, NB	1
Debré, B	1
Zerbib, M	1
Todd, N	1
Lieberman, R	1
Morin, S	1
Bastian, A	1
Marte, J	1
Tsang, KY	1
Beetham, P	1
Grosenbach, DW	1
Dahut, W	1
Malone, S	2
Perry, G	1
Segal, R	2
Dahrouge, S	1
Crook, J	1
Somogyi, A	1
Zuech, P	1
Cazaban, A	1
Chéreau, O	1
Nakabayashi, M	1
Regan, MM	1
Lifsey, D	1
Kantoff, PW	1
Taplin, ME	2
Oh, WK	1
Davis, NB	1
Ryan, CW	1
Stadler, WM	2
Vogelzang, NJ	2
Raina, R	1
Pahalajani, G	1
Agarwal, A	1
Zippe, C	1
Urushibara, M	1
Ishioka, J	1
Hyochi, N	1
Kihara, K	2
Hara, S	1
Singh, P	1
Isaacs, JT	1
Kageyama, Y	1
Lu, S	2
Wang, A	1
Dong, Z	1
Sartor, AO	1
Tangen, CM	1
Hussain, MH	1
Eisenberger, MA	1
Parab, M	1
Fontana, JA	1
Chapman, RA	1
Mills, GM	1
Raghavan, D	1
Crawford, ED	4
Bélanger, A	10
Dupont, A	11
Labrie, F	14
Raynaud, JP	12
Bonne, C	1
Moguilewsky, M	7
Lefebvre, FA	4
Cusan, L	4
Husson, JM	6
Fazekas, AT	5
Monfette, G	5
Laberge, JG	2
Emond, JP	2
Lacoursiere, Y	1
Gareau, J	1
Sandow, J	1
Faure, N	1
Lemay, A	1
Laroche, B	5
Robert, G	1
Plante, R	1
Jean, C	1
Thabet, M	1
Roy, R	1
Emond, J	1
Lacourciere, Y	2
Waxman, J	1
Pandha, H	1
Dijkman, GA	3
Fernandez del Moral, P	2
Debruyne, FM	4
Janknegt, RA	6
Abbou, CC	5
Bartoletti, R	1
Bernstein-Hahn, L	1
Bracken, B	1
Brisset, JM	2
Da Silva, FC	1
Chisholm, G	1
Akimoto, S	4
Masai, M	2
Kitagawa, N	1
Nakamura, T	1
Shimazaki, J	4
Chatelain, C	2
Rousseau, V	1
Cosaert, J	1
Decensi, A	4
Torrisi, R	3
Fontana, V	2
Warriar, N	1
Pagé, N	1
Koutsilieris, M	1
Govindan, MV	1
Matzkin, H	2
Braf, Z	1
Bertagna, C	5
De Géry, A	4
Hucher, M	3
François, JP	1
Zanirato, J	1
Marroni, P	2
Padovani, P	2
Guarneri, D	4
Minuto, F	1
Boccardo, F	5
Pescatore, P	1
Hammel, P	2
Durand, F	1
Bertheau, P	1
Bernuau, J	1
Huc, D	1
Gerbal, JL	1
Degott, C	1
Benhamou, JP	1
Gaillard-Moguilewsky, M	1
Ulmann, A	1
Fiet, J	4
Doré, JC	1
Gô, AL	1
Ojasoo, T	2
Pensa, F	1
McLeod, DG	1
Soloway, MS	2
Barthélémy, Y	1
Colombel, M	1
Gasman, D	1
Patard, JJ	1
Chopin, D	1
Joual, A	1
Rabii, R	1
Aboutaeib, R	1
el Moussaoui, A	1
Benjelloun, S	1
Dole, EJ	1
Holdsworth, MT	1
Kaisary, AV	1
Smith, JA	2
Huan, SD	1
Gerridzen, RG	1
Yau, JC	1
Stewart, DJ	1
Lange, PH	1
deGery, A	1
De Reijke, TM	1
Inomiya, H	1
Akakura, K	1
Ito, H	1
Eastham, JA	1
Lansiaux, P	1
Lucas, C	1
Leblanc, V	1
Boccon-Gibod, L	2
Mahler, C	1
Verhelst, J	1
Denis, L	2
Wieder, JA	1
Bonnet, P	1
Fourcade, RO	1
Fenton, MA	1
Shuster, TD	1
Fertig, AM	1
Kolvenbag, G	1
Bubley, GJ	1
Balk, SP	1
Schröder, FH	3
Crook, JM	1
Huan, S	1
Sarosdy, MF	1
Migliari, R	2
Muscas, G	1
Murru, M	1
Verdacchi, T	1
De Benedetto, G	1
De Angelis, M	1
Candas, B	1
Melezinek, I	1
Schmidt, A	1
Schmitt, B	1
Wilt, TJ	1
Schellhammer, PF	1
DeMasi, V	1
Collette, L	1
Studer, UE	1
Denis, LJ	1
Sylvester, RJ	1
Kolvenbag, GJ	1
Newling, DW	1
Shain, SA	3
Desai, A	1
Eaton, VS	1
Blackmore, TK	1
Higa, T	1
Isaka, S	1
Pfitzenmeyer, P	1
Foucher, P	1
Piard, F	1
Coudert, B	1
Braud, ML	1
Gabez, P	1
Lacroix, S	1
Mabille, JP	1
Camus, P	1
Gomez, JL	1
Tremblay, M	2
Decensi, AU	2
Martorana, G	2
Fioretto, L	1
Mini, E	1
Macaluso, MP	1
Giuliani, L	2
Santi, L	1
Periti, P	1
Scarpa, RM	1
Campus, G	1
De Lisa, A	1
Zucca, I	1
D'Atri, M	1
Serra, A	1
Usai, E	1
Paoletti, MC	2
Lalanne, JM	1
Merlo, F	1
Positano, N	1
Costantini, M	1
Akaza, H	1
Aso, Y	1
Niijima, T	1
Fuse, H	1
Izaka, S	1
Imai, K	1
Yamanaka, H	1
Nabors, WL	1
Ducreux, M	1
Bismuth, E	1
Ladouch-Badre, A	1
Benoit, G	1
Buffet, C	1
Etienne, JP	1
Pavone-Macaluso, M	4
Béland, G	5
Elhilali, M	4
Fradet, Y	4
Ramsey, EW	4
Trachtenberg, J	3
Venner, PM	4
Tewari, HD	3
Creaven, PJ	2
Pendyala, L	3
Tremblay, D	4
Du Plessis, DJ	1
Schuurmans, AL	1
Bolt, J	1
Veldscholte, J	1
Mulder, E	1
Mulders, PF	1
Theeuwes, AG	1
Serretta, V	3
Daricello, G	3
Pavone, C	3
Cacciatore, M	2
Romano, C	2
Cavallo, N	1
Namer, M	3
Toubol, J	2
Caty, A	1
Couette, JE	1
Douchez, J	1
Kerbrat, P	1
Droz, JP	1
Akoun, GM	1
Liote, HA	1
Liote, F	1
Gauthier-Rahman, S	1
Kuntz, D	1
Kuhn, JM	1
Billebaud, T	1
Navratil, H	2
Moulonguet, A	1
Grise, P	1
Louis, JF	1
Costa, P	1
Dahan, R	1
Furr, BJ	1
Knönagel, H	1
Bolle, JF	1
Hering, F	1
Senn, E	1
Hodel, T	1
Neuenschwander, H	1
Biedermann, C	1
Lamberts, SW	1
Uitterlinden, P	1
de Jong, FH	1
Monfette, JE	1
Huot, RI	2
Dupront, A	1
Meyer, BH	1
Pottier, J	3
Tournemine, C	3
Amiel, J	1
Moorjani, S	1
Lupien, PJ	1
Brun, D	1
Gagné, C	1
Giguère, M	1
Cotard, M	1
Proulx, L	1
Seigneur, J	1
Trechot, PF	1
Hubert, J	1
Lamy, P	1
Botto, H	1
Camey, M	1
Cariou, G	1
Duclos, JM	1
Duval, F	1
Gontiès, D	1
Jorest, R	1
Lamy, L	1
Le Goff, JM	1
Martin, PM	1
Huben, R	1
Rao, BR	1
Geldof, AA	1
van der Wilt, CL	1
de Voogt, HJ	1
Harnois, C	1
Malenfant, M	1
Coussediere, D	2
Salmon, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Phase II Study of Either Immunotherapy With a Regimen of Recombinant Pox Viruses That Express PSA/B7.1 Plus Adjuvant GM-CSF and IL2 or Hormone Therapy With Nilutamide in Patients With Hormone Refractory Prostate Cancer and No Radiographic Evi[NCT00020254]	Phase 2	0 participants	Interventional	2000-06-30	Completed
A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer[NCT01875250]	Phase 2	38 participants (Actual)	Interventional	2013-07-22	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	ng/dl (Median)
All Participants	834

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01875250)
Timeframe: Date treatment consent signed to date off study, approximately 43 months and 13 days for Arm A, and 78 months and 6 days for Arm B.

Percent Change in Prostate Specific Antigen (PSA) After 84 Days of Enzalutamide in Course 1

Tumor Growth Rate

Intervention	Participants (Count of Participants)
Arm A - Enzalutamide for 3 Months	19
Arm B - Enzalutamide for 3 Months + PSA-TRICOM	19

Intervention	Percent change (Median)
Arm A - Enzalutamide for 3 Months	-99
Arm B - Enzalutamide for 3 Months + PSA-TRICOM	-99

Growth rate was measured using the growth rate equation -f(t) = exp (-d*t) + exp (g*t) -1 where exp is the base of the natural algorithm, e = 2.7182 and t is days since treatment started. The tumor growth rate equation measures Prostate Specific Antigen (PSA) rise over time. The UOM is unitless because this is a way to measure PSA kinetics. (NCT01875250)
Timeframe: 7 months

Mean Pretreatment Plasma Vascular Endothelial Growth Factor (VEGF) Concentration 30 Days After the Start of Course 1 and Course 2 of Enzalutamide

Intervention	unitless (Number)
Arm A - Enzalutamide for 3 Months	0.031
Arm B - Enzalutamide for 3 Months + PSA-TRICOM	0.030

VEGF was measured by the enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantitation of assay was 9.0 pg/ml. (NCT01875250)
Timeframe: 30 Days After the Start of Course 1 and Course 2 of Enzalutamide

Median Time Until Prostate Specific Antigen (PSA) Recovery From Baseline Following Course 1 and Course 2 of Enzalutamide

Intervention	pg/ml (Mean)
	Course 1	Course 2
All Participants	192	165.04

PSA recovery is defined as the return above baseline PSA in participants with normal testosterone and non-metastatic, castration sensitive prostate cancer. (NCT01875250)
Timeframe: up to 41 months

Article	Year
Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis. Current clinical pharmacology, 2019, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Imidazolidines; Male; Neo	2019
[Hormonal treatment in prostate cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:15 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Co	2013
Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. European urology, 2002, Volume: 42, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Double-Bl	2002
Antiandrogen monotherapy: indications and results. Urology, 2002, Volume: 60, Issue:3 Suppl 1 Topics: Aged; Androgen Antagonists; Anilides; Castration; Flutamide; Humans; Imidazoles; Imidazolidines; Mal	2002
The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU international, 2003, Volume: 91, Issue:5 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Fluta	2003
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urologia internationalis, 2004, Volume: 72, Issue:2 Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Cyproterone Acetate; Flutamide; Humans; Imid	2004
Monotherapy in advanced prostate cancer: an overview. Experimental oncology, 2004, Volume: 26, Issue:3 Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality T	2004
The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. The Prostate, 1984, Volume: 5, Issue:3 Topics: Androgen Antagonists; Androgens; Animals; Drug Therapy, Combination; Feedback; Gonadotropin-Releasin	1984
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist]. Journal de pharmacologie, 1983, Volume: 14 Suppl 3 Topics: Acid Phosphatase; Androgen Antagonists; Buserelin; Drug Synergism; Drug Therapy, Combination; Gonado	1983
[Complete androgen blockage in the treatment of metastatic prostate cancer]. Harefuah, 1994, Mar-01, Volume: 126, Issue:5 Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Meta	1994
Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). British journal of urology, 1994, Volume: 73, Issue:4 Topics: Acid Phosphatase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tum	1994
Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies. Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl Topics: Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Double-Blind Method; Humans;	1993
Antiandrogenic drugs. Cancer, 1993, Feb-01, Volume: 71, Issue:3 Suppl Topics: Androgen Receptor Antagonists; Anilides; Cyproterone Acetate; Diethylstilbestrol; Drug Administratio	1993
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer, 1993, Feb-01, Volume: 71, Issue:3 Suppl Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cyproterone Acetate; Flutamide; Humans; Imida	1993
Nilutamide: an antiandrogen for the treatment of prostate cancer. The Annals of pharmacotherapy, 1997, Volume: 31, Issue:1 Topics: Androgen Antagonists; Anilides; Flutamide; Half-Life; Humans; Imidazoles; Imidazolidines; Male; Nitr	1997
[Conference on the treatment of prostatic cancer. Munich, Germany, 2-3 November 1996]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1997, Volume: 7, Issue:6 Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Combined Moda	1997
Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? European urology, 1998, Volume: 33, Issue:2 Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Flutamide; Humans; Imidazoles; Imidazolidi	1998
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clinical pharmacokinetics, 1998, Volume: 34, Issue:5 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Cyprotero	1998
The place and the results of monotherapy. Acta urologica Belgica, 1998, Volume: 66, Issue:2 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone	1998
Androgen deprivation for prostatic carcinoma: a rationale for choosing components. International journal of urology : official journal of the Japanese Urological Association, 1998, Volume: 5, Issue:4 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imida	1998
Antiandrogens as monotherapy for prostate cancer. European urology, 1998, Volume: 34 Suppl 3 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone	1998
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen. Anti-cancer drugs, 1999, Volume: 10, Issue:9 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Flutamide; Humans;	1999
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 1999, Volume: 71, Issue:5 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flut	1999
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (London, England), 2000, Apr-29, Volume: 355, Issue:9214 Topics: Aged; Androgen Antagonists; Cyproterone; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Orchie	2000
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU international, 2001, Volume: 87, Issue:1 Topics: Androgen Antagonists; Anilides; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines;	2001
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology, 2001, Volume: 57, Issue:4 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas	2001
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology, 2001, Volume: 58, Issue:2 Suppl 1 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imid	2001
Pharmacokinetics and metabolism of nilutamide. Urology, 1991, Volume: 37, Issue:2 Suppl Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Animals; Biological Availability; Dogs; Humans	1991
Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Urology, 1991, Volume: 37, Issue:2 Suppl Topics: Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolid	1991
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Progress in clinical and biological research, 1990, Volume: 359 Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidaz	1990
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer? Progress in clinical and biological research, 1990, Volume: 350 Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E	1990
Clinical applications of antiandrogens. Journal of steroid biochemistry, 1988, Volume: 31, Issue:4B Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans;	1988
Androgen blockade and suppression for prostate carcinoma. Lancet (London, England), 1989, Oct-28, Volume: 2, Issue:8670 Topics: Androgen Antagonists; Cyproterone; Drug Administration Schedule; Drug Therapy, Combination; Flutamid	1989
What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy. Progress in clinical and biological research, 1987, Volume: 243A Topics: Androgen Antagonists; Animals; Buserelin; Combined Modality Therapy; Humans; Imidazoles; Imidazolidi	1987
Proliferation of AXC/SSh rat prostate cancer cells in vitro is androgen modulated. Journal of steroid biochemistry, 1987, Volume: 27, Issue:1-3 Topics: Animals; Cell Division; Clone Cells; Imidazoles; Imidazolidines; Male; Mitogens; Neoplasms, Hormone-	1987
Pharmacological and clinical studies of the antiandrogen Anandron. Journal of steroid biochemistry, 1987, Volume: 27, Issue:4-6 Topics: Androgen Antagonists; Animals; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male;	1987
Design of antiandrogens and their mechanisms of action: a case study (anandron). Hormone research, 1987, Volume: 28, Issue:2-4 Topics: Androgen Antagonists; Androgens; Animals; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neopla	1987

Article	Year
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-15, Volume: 14, Issue:14 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Castration; Combined Modality Thera	2008
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. International journal of radiation oncology, biology, physics, 2009, Nov-15, Volume: 75, Issue:4 Topics: Aged; Androgen Antagonists; Buserelin; Drug Administration Schedule; Follow-Up Studies; Humans; Imid	2009
Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. European urology, 2002, Volume: 42, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Double-Bl	2002
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. The Journal of urology, 2005, Volume: 174, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cancer Vaccines; Disease Progression; Humans; Imidazo	2005
Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU international, 2005, Volume: 96, Issue:4 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Follow-	2005
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU international, 2005, Volume: 96, Issue:6 Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; F	2005
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Asian journal of andrology, 2007, Volume: 9, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone;	2007
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer, 2008, Volume: 112, Issue:11 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Fre	2008
Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group. European urology, 1995, Volume: 27, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Double-Blind Method;	1995
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. The Journal of urology, 1993, Volume: 149, Issue:1 Topics: Acid Phosphatase; Actuarial Analysis; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms	1993
French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. European urology, 1994, Volume: 26 Suppl 1 Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Goserelin; H	1994
Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect? British journal of cancer, 1994, Volume: 69, Issue:3 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Erythrocyte Count; Erythropoiesis; Hematocrit; He	1994
Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Combined Modality Thera	1993
Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy. The Prostate, 1993, Volume: 23, Issue:4 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bioma	1993
Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion. The Prostate, 1994, Volume: 24, Issue:1 Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Androstenedione;	1994
Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate. European urology, 1997, Volume: 31 Suppl 3 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Castration; Huma	1997
Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. The Journal of urology, 1997, Volume: 157, Issue:4 Topics: Acid Phosphatase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone	1997
Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. The Journal of urology, 1997, Volume: 158, Issue:1 Topics: Actuarial Analysis; Androgen Antagonists; Combined Modality Therapy; Disease Progression; Double-Bli	1997
[Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1997, Volume: 7, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic	1997
Intermittent androgen suppression in the management of prostate cancer. Urology, 1999, Volume: 53, Issue:3 Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Stud	1999
A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group. Cancer treatment and research, 1992, Volume: 59 Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male;	1992
Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer detection and prevention, 1991, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolid	1991
Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP). European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:9 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Drug Evaluation; Estradiol; Humans; Imidazoles; Imidazo	1991
[Clinical study of RU 23908 (nilutamide) in prostatic cancer]. Hinyokika kiyo. Acta urologica Japonica, 1991, Volume: 37, Issue:4 Topics: Administration, Oral; Androgen Antagonists; Drug Evaluation; Humans; Imidazoles; Imidazolidines; Mal	1991
Total androgen ablation: Canadian experience. The Urologic clinics of North America, 1991, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method	1991
Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study. Urology, 1991, Volume: 37, Issue:2 Suppl Topics: Acid Phosphatase; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imid	1991
Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Urology, 1991, Volume: 37, Issue:2 Suppl Topics: Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolid	1991
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Progress in clinical and biological research, 1990, Volume: 359 Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidaz	1990
Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer, 1990, Jun-15, Volume: 65, Issue:12 Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplasti	1990
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer? Progress in clinical and biological research, 1990, Volume: 350 Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E	1990
A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Dou	1990
Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group. Seminars in urology, 1990, Volume: 8, Issue:3 Topics: Actuarial Analysis; Aged; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Huma	1990
A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. The Journal of steroid biochemistry and molecular biology, 1990, Dec-20, Volume: 37, Issue:6 Topics: Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Imidazolidines;	1990
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). The New England journal of medicine, 1989, Aug-17, Volume: 321, Issue:7 Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Evaluation; Humans; Imidazoles; Imidaz	1989
[Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study]. Helvetica chirurgica acta, 1989, Volume: 56, Issue:3 Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imid	1989
Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study. American journal of clinical oncology, 1988, Volume: 11 Suppl 2 Topics: Aged; Androgen Antagonists; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; France	1988
Total androgen blockade vs orchiectomy in stage D2 prostate cancer. Progress in clinical and biological research, 1987, Volume: 243A Topics: Androgen Antagonists; Buserelin; Clinical Trials as Topic; Humans; Imidazoles; Imidazolidines; Male;	1987
Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study. Progress in clinical and biological research, 1987, Volume: 243A Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Busere	1987
Total androgen blockade for metastatic cancer of the prostate. American journal of clinical oncology, 1988, Volume: 11 Suppl 2 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality T	1988
Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. Progress in clinical and biological research, 1987, Volume: 243A Topics: Aged; Androgen Antagonists; Clinical Trials as Topic; Combined Modality Therapy; Humans; Imidazoles;	1987

Article	Year
Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera. Journal of medicinal chemistry, 2004, Nov-04, Volume: 47, Issue:23 Topics: Androgen Antagonists; Doxorubicin; Formaldehyde; Green Fluorescent Proteins; Humans; Imidazoles; Lig	2004
Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide. Journal of medicinal chemistry, 2008, Mar-27, Volume: 51, Issue:6 Topics: Androgen Antagonists; Anilides; Binding, Competitive; Cell Proliferation; Crystallography, X-Ray; Do	2008
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. British journal of cancer, 2017, Oct-10, Volume: 117, Issue:8 Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; Califor	2017
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. Cancer, 2019, 04-01, Volume: 125, Issue:7 Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hor	2019
Synthesis of Deuterium Labeled 5, 5-Dimethyl-3-(α, α, α-trifluoro-4-nitro-m-tolyl) Hydantoin. Current radiopharmaceuticals, 2019, Volume: 12, Issue:1 Topics: Androgen Antagonists; Deuterium; Humans; Hydantoins; Imidazoles; Imidazolidines; Male; Prostatic Neo	2019
A cerium vanadate interconnected with a carbon nanofiber heterostructure for electrochemical determination of the prostate cancer drug nilutamide. Mikrochimica acta, 2019, 07-27, Volume: 186, Issue:8 Topics: Antineoplastic Agents; Carbon; Cerium; Electrochemical Techniques; Electrodes; Humans; Hydrogen-Ion	2019
Lung caught in Nilutamide treatment. BMJ case reports, 2016, Sep-06, Volume: 2016 Topics: Aged, 80 and over; Androgen Antagonists; Anticholesteremic Agents; Antineoplastic Agents; Drug Thera	2016
Delayed dark adaptation caused by nilutamide. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2008, Volume: 28, Issue:2 Topics: Age Factors; Aged, 80 and over; Androgen Antagonists; Carcinoma; Dark Adaptation; Dose-Response Rela	2008
Watchful waiting beats androgen deprivation therapy in early prostate cancer. Journal of the National Cancer Institute, 2008, Nov-05, Volume: 100, Issue:21 Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions;	2008
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. International journal of radiation oncology, biology, physics, 2009, Oct-01, Volume: 75, Issue:2 Topics: Aged; Androgen Antagonists; Buserelin; Combined Modality Therapy; Humans; Imidazolidines; Male; Midd	2009
Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect. Annals of internal medicine, 2002, Oct-01, Volume: 137, Issue:7 Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Androgen Antagonists; Anilides; Antineoplastic Agents,	2002
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. The Journal of urology, 2003, Volume: 169, Issue:5 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Castration; Follow-Up Studies; Humans; Imidazoles	2003
[Fatal fulminating hepatitis induced by nilutamide]. Gastroenterologie clinique et biologique, 2003, Volume: 27, Issue:12 Topics: Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatal Outcome; Humans; Imidazol	2003
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? The Canadian journal of urology, 2005, Volume: 12, Issue:1 Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Buserelin; Clinical Trials, Pha	2005
Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology, 2005, Volume: 65, Issue:4 Topics: Aged; Androgen Antagonists; Cyproterone Acetate; Follow-Up Studies; Humans; Imidazolidines; Male; Mi	2005
[From the finger to the eye!...]. La Revue de medecine interne, 2005, Volume: 26 Suppl 2 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco	2005
Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU international, 2005, Volume: 96, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazolidines;	2005
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. The Prostate, 2007, Jun-01, Volume: 67, Issue:8 Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone	2007
A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Molecular cancer therapeutics, 2007, Volume: 6, Issue:7 Topics: Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Proliferation; Dihyd	2007
Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. The Journal of clinical endocrinology and metabolism, 1984, Volume: 59, Issue:3 Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Buserelin; Castration; Combined	1984
New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Hormone research, 1983, Volume: 18, Issue:1-3 Topics: Androgen Antagonists; Animals; Buserelin; Drug Therapy, Combination; Gonadal Steroid Hormones; Gonad	1983
New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. Journal of steroid biochemistry, 1983, Volume: 19, Issue:1C Topics: Androgen Antagonists; Animals; Buserelin; Castration; Dihydrotestosterone; Drug Therapy, Combination	1983
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. The Prostate, 1983, Volume: 4, Issue:6 Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Hormones; Humans	1983
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. The Prostate, 1983, Volume: 4, Issue:6 Topics: Acid Phosphatase; Aged; Androgen Antagonists; Bone and Bones; Buserelin; Castration; Drug Therapy, C	1983
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 1984, Volume: 81, Issue:12 Topics: Acid Phosphatase; Adenocarcinoma; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans	1984
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clinical and investigative medicine. Medecine clinique et experimentale, 1982, Volume: 5, Issue:4 Topics: Adenocarcinoma; Androgen Antagonists; Animals; Bone Neoplasms; Buserelin; Drug Therapy, Combination;	1982
Anti-androgens in treatment of prostate cancer. Lancet (London, England), 1995, Oct-14, Volume: 346, Issue:8981 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cyproterone; Flutamide; Humans	1995
[Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1993, Volume: 84, Issue:3 Topics: Acid Phosphatase; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Humans; Imidazoles	1993
Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. The Prostate, 1994, Volume: 24, Issue:4 Topics: Amino Acid Sequence; Androgen Antagonists; Binding, Competitive; Blotting, Western; Chloramphenicol	1994
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. Acta endocrinologica, 1993, Volume: 129, Issue:4 Topics: Aged; Androgen Antagonists; Endocrine Glands; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Im	1993
[Fatal fulminant hepatitis induced by nilutamide (Anandron)]. Gastroenterologie clinique et biologique, 1993, Volume: 17, Issue:6-7 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Drug Interaction	1993
Pharmacology of nilutamide. Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Pros	1993
[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1996, Volume: 6, Issue:1 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant;	1996
Nilutamide approved for metastatic prostate cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Dec-01, Volume: 53, Issue:23 Topics: Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Humans; Imidazoles; Imidazol	1996
[An unusual presentation of prostate cancer]. Annales d'urologie, 1996, Volume: 30, Issue:5 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Humans; Imidazole	1996
Antiandrogen monotherapy in the management of advanced prostate cancer. European urology, 1997, Volume: 31 Suppl 2 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imid	1997
Antiandrogen withdrawal syndrome with nilutamide. Urology, 1997, Volume: 49, Issue:4 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Humans; Imidazoles; Imidazolidines; M	1997
Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase. Japanese journal of clinical oncology, 1997, Volume: 27, Issue:4 Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Androgen Anta	1997
Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer. The Journal of urology, 1998, Volume: 159, Issue:3 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Prog	1998
Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer. The Journal of urology, 1998, Volume: 159, Issue:6 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined	1998
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:8 Topics: Amino Acid Substitution; Androgen Antagonists; Androgens; Androstenedione; Animals; beta-Galactosida	1997
Androgen blockade in prostate cancer. Lancet (London, England), 2000, Jul-22, Volume: 356, Issue:9226 Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta	2000
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. The Prostate, 2001, Jun-15, Volume: 48, Issue:1 Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Ana	2001
Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer. Molecular urology, 2001,Autumn, Volume: 5, Issue:3 Topics: Androgen Antagonists; Anilides; Animals; Cell Division; Cell Survival; Culture Media, Serum-Free; Fi	2001
Nilutamide: possible utility as a second-line hormonal agent. Urology, 2001, Volume: 58, Issue:6 Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Prostate-Spec	2001
Nilutamide-induced neutropenia. BJU international, 2001, Volume: 88, Issue:7 Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Middle Aged;	2001
Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray. Advances in experimental medicine and biology, 1992, Volume: 324 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Combined Modality Therapy; Estrogens	1992
Nilutamide pneumonitis: a report on eight patients. Thorax, 1992, Volume: 47, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Lung; Male; Midd	1992
Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. The American journal of medicine, 1992, Volume: 92, Issue:5 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemother	1992
Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer. Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences, 1991, Volume: 63, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Follow-Up St	1991
Maximal androgen blockade in prostatic cancer. Scandinavian journal of urology and nephrology. Supplementum, 1991, Volume: 138 Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolid	1991
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. The Journal of urology, 1991, Volume: 146, Issue:2 Topics: Androgen Antagonists; Antineoplastic Agents; Carcinoma; Drug Evaluation; Drug Tolerance; Humans; Imi	1991
Total androgen ablation: American experience. The Urologic clinics of North America, 1991, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Flutamide; Gonadotropin-Releas	1991
[Nilutamide-induced acute hepatitis]. Gastroenterologie clinique et biologique, 1991, Volume: 15, Issue:6-7 Topics: Acute Disease; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Imidazol	1991
Are organ preservation and maintenance of sexual function compatible with optimal management of prostate cancer? Part 2--Advanced cancer. Progress in clinical and biological research, 1991, Volume: 370 Topics: Androgen Antagonists; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Humans; Imidazoles	1991
Anandron: a new step in the treatment of advanced prostate cancer. Proceedings of a symposium. June 12, 1989. Urology, 1991, Volume: 37, Issue:2 Suppl Topics: Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms	1991
Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. The Journal of steroid biochemistry and molecular biology, 1990, Dec-20, Volume: 37, Issue:6 Topics: Acid Phosphatase; Androgen Antagonists; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Erb	1990
Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis. Chest, 1990, Volume: 97, Issue:2 Topics: Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Humans; I	1990
Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens. Annals of the New York Academy of Sciences, 1990, Volume: 595 Topics: Androgen Antagonists; Carcinoma; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neop	1990
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies. Hormone research, 1989, Volume: 32 Suppl 1 Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazol	1989
[Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate]. Archivos espanoles de urologia, 1989, Volume: 42 Suppl 2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Th	1989
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue. Cancer research, 1988, Nov-01, Volume: 48, Issue:21 Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Pr	1988
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]. Annales d'urologie, 1986, Volume: 20, Issue:2 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Flutam	1986
Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen. Cancer research, 1986, Volume: 46, Issue:8 Topics: Androgen Antagonists; Androgens; Animals; Cell Division; Cell Line; Dehydroepiandrosterone; Dehydroe	1986
The kinetics of antiandrogens in humans. Progress in clinical and biological research, 1987, Volume: 243A Topics: Androgen Antagonists; Anilides; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imi	1987
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. Journal of steroid biochemistry, 1986, Volume: 24, Issue:1 Topics: Androgen Antagonists; Animals; Buserelin; Diethylstilbestrol; Humans; Imidazoles; Imidazolidines; Ki	1986
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism: clinical and experimental, 1987, Volume: 36, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Ch	1987
Pulmonary complications of hormone treatment in prostate carcinoma. Chest, 1988, Volume: 93, Issue:5 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles	1988
Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate. Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:1 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Blood Proteins; Dose-Response Relationship, Drug; Hum	1988
Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer. The Prostate, 1988, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Prepa	1988
Ocular toxicity of Anandron in patients treated for prostatic cancer. The British journal of ophthalmology, 1986, Volume: 70, Issue:6 Topics: Aged; Androgen Antagonists; Flutamide; Humans; Imidazoles; Imidazolidines; Light; Male; Middle Aged;	1986
[Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment]. Bulletin du cancer, 1986, Volume: 73, Issue:1 Topics: Androgens; Animals; Feedback; Hypothalamo-Hypophyseal System; Imidazoles; Imidazolidines; Kinetics;	1986
Pharmacology and clinical studies with RU 23908 (Anandron). Progress in clinical and biological research, 1985, Volume: 185A Topics: Androgen Antagonists; Androstenedione; Animals; Castration; Diethylstilbestrol; Flutamide; Humans; I	1985

nilutamide and Cancer of Prostate